GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Two divergent haplotypes from a highly heterozygous lychee genome suggest independent domestication events for early and late-maturing cultivars
    Springer Science and Business Media LLC ; 2022
    In:  Nature Genetics Vol. 54, No. 1 ( 2022-01), p. 73-83
    Details
    In: Nature Genetics, Springer Science and Business Media LLC, Vol. 54, No. 1 ( 2022-01), p. 73-83
    Abstract: Lychee is an exotic tropical fruit with a distinct flavor. The genome of cultivar ‘Feizixiao’ was assembled into 15 pseudochromosomes, totaling ~470 Mb. High heterozygosity (2.27%) resulted in two complete haplotypic assemblies. A total of 13,517 allelic genes (42.4%) were differentially expressed in diverse tissues. Analyses of 72 resequenced lychee accessions revealed two independent domestication events. The extremely early maturing cultivars preferentially aligned to one haplotype were domesticated from a wild population in Yunnan, whereas the late-maturing cultivars that mapped mostly to the second haplotype were domesticated independently from a wild population in Hainan. Early maturing cultivars were probably developed in Guangdong via hybridization between extremely early maturing cultivar and late-maturing cultivar individuals. Variable deletions of a 3.7 kb region encompassed by a pair of CONSTANS -like genes probably regulate fruit maturation differences among lychee cultivars. These genomic resources provide insights into the natural history of lychee domestication and will accelerate the improvement of lychee and related crops.
    Type of Medium: Online Resource
    ISSN: 1061-4036 , 1546-1718
    URL: Article
    DOI: 10.1038/s41588-021-00971-3
    RVK:
    XA 10000
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2022
    detail.hit.zdb_id: 1494946-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Abstract 4051: Anlotinib inhibits the progress of colorectal cancer cells by antagonizing glycolysis & JAK2-STAT3 signaling
    American Association for Cancer Research (AACR) ; 2020
    In:  Cancer Research Vol. 80, No. 16_Supplement ( 2020-08-15), p. 4051-4051
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 4051-4051
    Abstract: Background: Anlotinib is a novel multi-target tyrosine kinase receptor inhibitor (TKI) that has been proved to treat advanced NSCLC as a third-line regime in China. This study designed to investigate the effectiveness & possible mechanism of anlotinib colorectal cancer (CRC) therapy. Methods: CCK-8 assay & CyQUANT NF assay were used to detect the sensitivity of CRC cells to DDP & anlotinib. Real time quantitative polymerase chain reaction was used to detect the mRNA level of hub genes. The protein expression of pVEGFR2, cleaved PARP, cleaved caspase 3, JAK2, pJAK2, STAT3 & PSTAT3 were determined by western blot. The roles of DDP & anlotinib in the progression, invasion & metastasis of CRC cells were evaluated by colony formation, wound healing & trans-well assay. Lactate release & glucose consumption were measured to investigate glucose metabolism. Cell apoptosis was analyzed by Hoechst33342 fluorescence staining & flow cytometer. Results: We found that anlotinib may improve the treatment of CRC by blocking the effects of VEGFA. Subsequently, in vitro assays demonstrated that anlotinib & /or DDP inhibited cell proliferation, migration & invasion & also activated apoptosis in human colorectal cancer cells. Additionally, glucose metabolism in CRC HCT-116 & LOVO cells was suppressed by anlotinib & /or DDP. In other hand, anlotinib & /or DDP may improve the treatment of CRC by inhibiting JAK2-STAT3 signaling pathway. Conclusions: Our preclinical studies showed that anlotinib inhibited cell proliferation, invasion, migration & activated apoptosis by antagonizing glycolysis & JAK2-STAT3 signaling. Combination chemotherapy of anlotinib with cisplatin is more sensitive to CRC. Citation Format: Zhenxian Jia, Zhi Zhang, Ze Li, Ang Li, Yuning Xie, Hongjiao Wu, Zhenbang Yang, Hongmei Zhang, Xuemei Zhang. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing glycolysis & JAK2-STAT3 signaling [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4051.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2020-4051
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...